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Abstract
Glucocorticoids (GC) modulate immune function in a number of
ways, including suppression of T cell proliferation and other
IL-2-mediated T cell functions. These inhibitory effects are
similar to those induced by transforming growth factor-,il
(TGF-,61), a cytokine with potent T cell inhibiting activities.
We examined the hypothesis that GC effects may be at least
partially achieved through modulation of the expression of the
TGF-,B1 gene in activated T cells. Normal T cells were cultured
with or without purified phytohemagglutinin (PHA-p) and 4,8-
phorbol 12-myristate 13-acetate (PMA) in the presence or ab-
sence of the synthetic GC, dexamethasone (100-200 /g/ml).
The production of latent and active forms of TGFjO by these
cells were analyzed by immunoblotting and bioassays. The
steady-state levels of TGF-ft1 mRNA were analyzed in total
RNA from these cells by Northern hybridizations using a hu-
man TGF-ft1 cDNA. The results showed that dexamethasone
caused an increase in TGFj# production and a dose-dependent
two to fourfold increase in TGF-,61 mRNA in activated as well
as in unstimulated T cells, 1 h after exposure of the cultures to
the steroid. The increase in TGF-,61 mRNA levels by dexameth-
asone was further potentiated two to threefold by cyclohexi-
mide, suggesting that the steroid effect may be due to inhibition
of the synthesis of proteins that decrease TGF-,81 gene tran-
scription or the stability of its transcripts. Finally, in vitro nu-
clear transcription studies indicated the dexamethasone effects
on TGF-ftl gene expression to be largely transcriptional. (J.
Clin. Invest. 1991. 88:1574-1580.) Key words: transforming
growth factor 0 * glucocorticoids *T cell activation * dexametha-
sone
Introduction
Glucocorticoids (GC)1 are immunosuppressive and can induce
lympholysis in vitro and in vivo. Although these properties
have resulted in the wide clinical application of GC as antiin-
flammatory and antineoplastic agents, the mechanisms by
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1. Abbreviations used in this paper: GAPD, glyceraldehyde-3-phos-
phate dehydrogenase; GC, glucocorticoids; PHA-p, purified phytohe-
magglutinin; TGF-#,1, transforming growth factor-$31.
which they modulate immune system function are unclear.
One possibility, supported by accumulating experimental evi-
dence, is that GC inhibit the synthesis and release ofimmuno-
regulatory molecules, such as IL-2 and y-IFN, by activated T
cells (1-5). These lymphokines promote the expansion of anti-
gen-specific helper/inducer or cytotoxic/suppressor T cell
clones as well as natural killer cells that are involved in immune
regulation and surveillance (6). The steady-state mRNA levels
ofboth IL-2 and y-IFN are significantly decreased when T cells
are activated in vitro with purified phytohemagglutinin (PHA-
p) and phorbol myristate acetate (PMA) in the presence of
dexamethasone (4). The inhibitory effects ofGC on immuno-
regulatory T cell functions in vivo was demonstrated in studies
that showed inhibition ofboth IL-2 and IL-2 receptor (IL-2R)
gene expression in activated T cells from GC-treated patients
with pulmonary sarcoidosis (7, 8). Recently, it has been shown
that transforming growth factor-,Bl (TGF-#31) (9), a cytokine
produced by mitogen-activated T cells, B cells, monocytes, and
fibroblasts, is a potent inhibitor of multiple T cell functions in
vitro (10-17). In common with the other members of the
TGFB gene family, TGF-3l1 has profound stimulatory effects
on fibroblast chemotaxis and on expression ofthe genes for the
extracellular matrix proteins collagen and fibronectin (18). Fur-
thermore, it has been shown that TGF-,B1 can upregulate its
own production by these cells (19). Although several target
genes regulated by TGF-,B1 have been identified in a variety of
human cells and cell lines, little is known about the mecha-
nisms that regulate the expression of the TGF-j31 gene.
The immunosuppressive effects of GC and TGF-tl on T
lymphocytes share important similarities. Both inhibit IL-2-
mediated T cell functions, such as lectin- and IL-2-induced T
cell proliferation and generation of regulatory T cells in vitro
(20-22) and in vivo (23, 24). For this reason, we investigated
whether GC altered the TGF-,B1 gene expression in mitogen-
activated human T cells. Our results show that dexamethasone
significantly increases the expression of the TGF-,B1 gene and
its protein product in these cells. Its effect on the TGF-j31 gene
is observed as early as 1 h after T cell induction with PHA-p/
PMA. The enhancement of the steady-state TGF-tll mRNA
levels in response to cycloheximide and the results of in vitro
nuclear transcription studies indicate that dexamethasone may
regulate TGF-, I gene expression at a transcriptional level.
Methods
Cells. PBMC, 2 x 108-2.5 x I09 were isolated by density gradient
separation from buffy coat by-products of whole blood donated by
healthy volunteers (Interstate Blood Bank, Philadelphia, PA). Buffy
coats from 20 different donors, 21-31 yr old, were studied. Adherent
cell-depleted T cells were prepared by incubating the PBMC in plastic
petri dishes for 4 h and passing the nonadherent cells twice over nylon
wool columns (25). Purity of nylon wool nonadherent T cell popula-
tions was determined by flow cytometry and histocytochemistry, using
an FITC-conjugated anti-pan T cell MAb anti-CD2 (Becton Dickin-
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son Immunocytometry Systems, Mountain View, CA), and a phycoer-
ythrin-conjugated MAb anti-CD14 (Becton Dickinson) which reacts
with cells ofmonocytic origin. Flow cytometric determination ofmem-
brane immunofluorescence with two color analysis (26) showed that T
cells were > 98% CD2+ and < 1% CD14+ when compared with non-
binding FITC- and phycoerythrin-labeled MAbs; < 1% cells reacted
with alpha-naphthyl-acetate esterase. Viability was > 99% as assessed
by trypan blue dye exclusion.
Activation of T cells and culture conditions. CD2+ lymphocytes
were cultured at 2 X 106/ml in RPMI 1640 (Gibco Laboratories, Grand
Island, NY) supplemented with 5% defined pooled human AB serum
(Gibco), penicillin 100 U/ml, streptomycin (100 Mg/ml) in 25-cm2 tis-
sue culture flasks (Coming Glass Works, Coming, NY) in a humidified
5% CO2 incubator at 370C. T cells were stimulated with 2 jtg/ml PHA-
p (Wellcome Diagnostics, Research Triangle Park, NC) and 30 ng/ml
PMA (Sigma Chemical Co., St. Louis, MO) at 370C for 1-72 h. In
some experiments, the human AB serum was omitted from cultures
that were harvested at I h. Dexamethasone (ESI Pharmaceuticals,
Cherry Hill, NJ) (100 g/ml-200 ug/ml) was added to T cell cultures as
indicated, the incubations were stopped at appropriate serial time
points, and cells were harvested for RNA extraction. In some experi-
ments 30 ng/ml cycloheximide (Sigma), was added to cultures at the
times indicated. To quantitate TGF-(lI levels, supernatants were ob-
tained from T cells cultured in serum-free Aim V medium (Gibco) in
the presence or absence ofPHA-p (2 ,g/ml)/PMA (30 ng/ml) with or
without dexamethasone (20-100 jug/ml), for 96 h. Supernatants were
brought to 1 M final concentration with acetic acid, and were incu-
bated for 10 min-2 h at room temperature to activate latent TGF-,B1.
Samples were neutralized to pH 7.0-7.4, Iyophilized to dryness, and
resuspended in 100 1l of 0.1% BSA (Sigma) in Dulbecco's modified
Eagle's medium (Gibco).
RNA isolation and Northern hybridizations. Total RNA was iso-
lated from cells using guanidinium isothiocyanate, according to the
method ofChirgwin et al. (27). RNA content ofindividual samples was
equalized by ethidium bromide staining of previously run 1% nonde-
naturing agarose gels. The samples containing equal amounts ofRNA
were then separated on 1% agarose-formaldehyde gels and transferred
to Hybond-N nylon membranes (Amersham Corp., Arlington Heights,
IL). Nick translated, [a-32P] dCTP-labeled cDNA was hybridized to the
filters in 50% formamide, 0.1% SDS, lx Denhardt's solution, 2X stan-
dard saline citrate (SSC; Ix SSC is 0. 15 M NaCl and 0.0 15 M sodium
citrate), 50 ng/ml salmon sperm DNA, with a sp act of 3-4 x 101
cpm/,ug, at 42°C for 16-20 h. After hybridization, filters were washed
twice for 5 min at 22°C in Ix SSC-0. 1% SDS, then twice for 30 min at
55°C in 0.1X SSC-0.1% SDS. Autoradiography was performed by ex-
posing to XAR film (Eastman Kodak Co., Rochester, NY) at -70°C.
Quantitation ofthe radioactive band intensities in autoradiographs was
performed by scanning laser densitometry and the areas under tracings
expressed as a fold increase relative to control samples as indicated.
DNA probes. The TGF-,ll probe is a gel purified 1.05-kb cDNA
insert cloned in pSB64, that hybridizes to a 2.5-kb TGF-fll mRNA
(kindly donated by Dr. Richard Derynck, Genentech) (28). Mouse gly-
ceraldehyde-3-phosphate dehydrogenase (GAPD) cDNA in pBR322
that hybridizes to a 1.7-kb GAPD mRNA was used as a control probe.
Nuclear transcription and isolation oflabeled RNA. Transcription
was measured in a nuclear runofftranscription assay (29). For prepara-
tion ofnuclei, 2 x 108 cells were suspended in 9 ml ofcold bufferA (0.3
M sucrose, 10 mM NaCI, 5 mM MgCl2, 10 mM Tris, pH 7.5, 0.5 mM
dithiothreitol). 1 ml of 10% Triton X-100 was added, cells were homog-
enized with a nuclei homogenizer (Con-Torque power unit; Eberbach
Corp., Ann Arbor, MI) three times at 300 rpm and the homogenate
centrifuged 5 min at 2,500 rpm. The pellet was washed and resus-
pended in 50 ,d ofbuffer B (40% glycerol, 50mM Tris-HCl buffer at pH
8.0, 5 mM MgCl2, 0.1 mM EDTA), and were stored at -700C. For
preparation ofcDNA filters, plasmids were purified by CsCl centrifuga-
tion, plasmid DNA was linearized by digestion with restriction en-
zymes, and denatured in 0.4 M NaOH at 370C for 15 min and then
neutralized with 0.4 vol of 5 M ammonium acetate. The solution was
diluted with lOx SSC and S Mg ofDNA was applied to nitrocellulose
using a dot blot apparatus (Schleicher and Schuell, Keene, NH). Filters
were UV crosslinked (Stratagene Cloning Systems, La Jolla, CA) and
prehybridized for 4 h at 420C with continuous shaking. Transcription
reactions were carried out in a vol of 100 Ml containing 40 M ofnuclei in
10mM Tris, (pH 8.0), 90mM KC1, 3mM MgCl2, 2mM dithiothreitol,
0.04 mM EDTA, 16% glycerol, 1 U/Mi RNAsin (Promega Biotec,
Madison, WI), 0.4 mM each of ATP, UTP, and GTP, and 500 MCi
[32P]-CTP (800 Ci/mmol; ICN Pharmaceuticals, Inc., Irvine, CA). In-
cubations were for 20 min at 250C, and incorporation of[32P]-CTP was
followed by TCA precipitation of l-Ml aliquots. Transcription was ter-
minated by addition of 900 Ml of buffer C (100 mM NaCl, 10 mM
Tris-HC1 buffer at pH 7.5, 2 mM KCI, 1 mM EDTA, and 0.5% SDS).
The samples were digested with 100 Mg/ml proteinase K for 60 min at
42°C after the addition of yeast tRNA (100 Mg in 10 Ml H20). Samples
were extracted with phenol/chloroform, adjusted to 10% TCA and 10%
saturated sodium pyrophosphate, and nucleic acids precipitated. Sam-
ples were then centrifuged for 10 min at 4°C, and pellets were washed
with 70% ethanol, dried, and dissolved in 100 Ml buffer with 10 mM
Tris, 1 mM EDTA, and 0.1% SDS. An additional 100Mg ofyeast tRNA
was added, and nucleic acids were ethanol precipitated from 2.5 M
ammonium acetate. The pellets were dissolved in 100 Ml of buffer that
contained 20 mM Tris-HCl, 10mM MgCI2, and 2 mM CaCl2, pH 7.5,
and incubated for 30 min at 37°C with 100 Mg/mI RNAse-free DNAse
(Promega) and 1 U/Ml RNAsin. Samples were extracted with phenol/
chloroform, and ethanol precipitated from 0.3 M sodium acetate. La-
beled transcripts were resuspended in prehybridization buffer, and 5 Ml
TCA were precipitated and counted. 8.5-10.5 X 106 cpm of each sam-
ple were adjusted to 400 M in the same buffer and hybridized to the
filters with appropriate probes with continuous shaking at 42°C for 72
h. The filters were washed for 15 min in 2X SSC and treated with
RNaseA (10 Mg/ml in 2x SSC) for 15 min at 37°C; washed in 2X SSC,
0.1%, SDS for 15 min at room temperature and for 15 min at 60°C;
dried and exposed to film, then cut out and 32p content directly deter-
mined in a scintillation counter.
TGF-flJ assay. The CCL64 assay was performed as described by
Tucker et al. (30). In brief, CCL64 cell line obtained from American
Type Culture Collection, Bethesda, MD, was maintained in DMEM
(Gibco), supplemented with penicillin (100 U/mi), streptomycin (100
Mg/ml), and 10% defined fetal calf serum (Gibco) in a humidified 5%
CO2 incubator at 37°C. To assay for TGF-#1, 6 X I04 cells/well were
grown in 24-well tissue culture plates (3548; Costar Corp., Cambridge,
MA) until nearly confluent when media was changed to DMEM 5%
FCS. After 24 h, 300 M1 of each supernatant was added to triplicate
wells. Unless otherwise stated, each supernatant was tested in dilutions
of 1:10, 1:100, 1:1,000, and 1:10,000. After 24 h incubation, the cells
were pulsed with [3H] thymidine (2 MCi/ml) for 4 h, the medium was
removed, and the cell layers were washed with 1 ml of ice cold 10%
TCA for 10 min. Cells were solubilized in 250 Ml of 0.25 N NaOH for
10 min and harvested using a microculture harvesting device and
counted in liquid scintillation counter to measure [3H] thymidine up-
take. For each assay a standard curve was obtained with 4 ng-l pg/ml
of a purified human TGF-#1 standard (Rand D Systems, Inc., Minne-
apolis, MN). Results were expressed as counts per minute. To neutral-
ize TGF-,B1 activity, a rabbit anti-TGF-61 (AB-IO-NA, R and D Sys-
tems) was added at 1:500 and 1:1,000 dilutions.
Immunoblot analysis for TGF-,81. Equal volume aliquots of the
supernatants were slot-blotted on nitrocellulose membranes, using a
slot-blot apparatus (Bio-Dot SF; Bio-Rad Laboratories, Richmond,
CA) according to manufacturer's instructions. Membranes were then
reacted with a rabbit polyclonal antibody to TGF-i1, (AB-20-PB, R
and D Systems) and the bound antibody visualized with horseradish
peroxidase-coupled goat anti-rabbit IgG.
Results
Stimulation ofTGF-#J gene expression in activated Tcells. To
determine the expression of the TGF-#lI gene by T cells, other
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mononuclear cells that produce TGF-,l were removed. Since
T cells cannot be induced to produce IL-2, to express high
affinity IL-2 receptors, or to proliferate by PHA-p alone in the
absence ofadherent cells (6, 30, 31), PMA was also added to T
cell cultures. The phorbol ester is the most effective substitute
for adherent cells in activating adherent cell-depleted T cells
with mitogen. To confirm the expression of TGF-#lI gene by
human T cells, adherent cell depleted-T cells were cultured
with or without PHA-p/PMA for 24 h. Total RNA from these
cells was isolated and examined by Northern hybridization
with the TGF- Il cDNA. To determine the baseline TGF-#lI
mRNA levels, T cells were subjected to RNA extraction imme-
diately after they were isolated from the nylon wool columns.
Fig. 1 shows the steady-state levels ofTGF-ft I mRNA in resting
(a), cultured but unstimulated (b), and PHA-p/PMA-stimu-
lated (c) T cells from one individual. Clearly detectable levels of
TGF-#3I mRNA were found in resting T cells that were pro-
cessed immediately after isolation. T cells that were cultured in
the absence of mitogens for 24 h in medium containing 5%
human AB serum expressed three to four times more TGF-,3 1
mRNA (Fig. 1 b) than resting T cells. This pattern of response
to dexamethasone was consistently observed in all individuals
studied. In T cells from the 20 donors, the increase in TGF-0 I
mRNA expression after culture for 24 h was 3.8±0.7 (2 SD)-
fold compared to resting T cells. Stimulation ofT cells for 24 h
with PHA-p (2 gg/ml) and PMA (30 ng/ml) resulted in a
16.8±0.9 (2 SD)-fold increase in TGF-# I mRNA compared to
the resting T cells (P < 0.01). To rule out the possible upregula-
tion ofTGF-,B1 mRNA by TGF-# I that may have been present
in the serum used, T cells were also cultured in the absence of
serum for 24 h. Steady-state TGF-f3l mRNA levels in T cells
cultured with or without serum were not different (data not
shown).
Effect ofdexamethasone on steady-state TGF-fl1 mRNA in
Tcells. To determine the effects ofdexamethasone on TGF-,lB
steady-state mRNA levels, adherent cell-depleted T cells from
15 individuals were cultured with or without PHA-p/PMA in
the presence of dexamethasone. A representative experiment
from one individual donor is shown in Fig. 2. Dexamethasone
(100 jg/ml or 200 ,ug/ml), in the absence of mitogens, resulted
in a 4.2±0.6 (2 SD)- and 7.1±0.8 (2 SD)-fold increase, respec-
tively, in TGF-(#l mRNA levels compared to T cells cultured
a b C Figure 1. Steady-state
TGF-81 mRNA levels
in stimulated anq un-
stimulated peripheral
blood T cells from one
individual. Northern
hybridization analyses
were performed on total
RNA. Cells were either
resting (a), cultured for
24 h without stimula-
tion (b), or exposed for
24 h to PHA-p (2 ug/ml)
2.5kb- _ and PMA (30 ng/ml)W (c). Upper part of the
figure shows the ethid-
ium bromide-stained
formaldehyde gel with bands corresponding to 28S and 18S ribosomal
RNA. 5 jg of total RNA was loaded in each lane.
a b c
1.n
Figure 2. Effect of dexamethasone on TGF-#l mRNA levels in un-
activated T cells from one individual. Northern hybridization analy-
ses were performed on total RNA from T cells that were either cul-
tured for 24 h without stimulation (a), or treated for 24 h with dexa-
methasone 100 gg/ml (b), or 200 qg/ml (c). 5 gg of total RNA was
loaded in each lane.
without dexamethasone (P < 0.01) (Fig. 2 a). Dexamethasone
induced a concentration-dependent increase in steady-state lev-
els mRNA in PHA-p/PMA treated T cells, as well (Fig. 3). In
15 donors, the increase in TGF-#l mRNA levels in PHA-p/
PMA stimulated T cells after 24 h ofincubation with 100 ,ug/ml
and 200 gg/ml dexamethasone was 3.2±0.5 (2 SD)- and
6.2±0.4 (2 SD)-fold respectively. As shown in Fig. 4, the stimu-
latory effect ofdexamethasone was detected as early as 1 h after
it was added to T cells. TGF-,lB mRNA levels were two and
fourfold greater in T cells induced for 1 h or 2 h with PHA-p/
PMA in the presence of 100 ug/ml dexamethasone, compared
a b c
2.5 k b -
Figure 3. Effect of dexamethasone on TGF-,B1 mRNA levels in acti-
vated T cells from one individual. Cells were either treated for 24 h
with PHA-p (2 jg/ml)/PMA (30 ng/ml), in the absence of dexameth-
asone (a), or in the presence of 100 jg/ml dexamethasone (b), or 200
jg/ml dexamethasone (c). 5 jg of total RNA was loaded in each lane.
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Figure 4. Time course of dexamethasone action on the levels of
TGF-,61 mRNA in T cells from one individual activated with PHA-
p/PMA. Northern hybridization analyses were performed on total
RNA from T cells treated with PHA-p (2 ug/ml)/PMA (30 ng/ml)
for 1, 2, or 4 h in the presence or absence of dexamethasone (100
ug/ml) and 6 h in the presence of dexamethasone (100 gg/ml). 5 ug
oftotal RNA was loaded in each lane. Lower part of the figure shows
the ethidium bromide-stained formaldehyde gel with bands corre-
sponding to 28S and 18S ribosomal RNA.
to those that did not receive dexamethasone. Similar results
were obtained in experiments with T cells from four additional
individuals. The dexamethasone-induced increase in TGF-#lI
mRNA levels reached a peak at 4-6 h and persisted for at least
24 h, as long as dexamethasone and the mitogens were present
in the culture medium (data not shown).
We next investigated whether the presence of dexametha-
sone at the initiation ofT cell activation was necessary for its
stimulatory effect on TGF-fli mRNA levels. As illustrated in
Fig. 5, when dexamethasone (100 ug/ml) was added as late as
12 h after T cell stimulation by PHA-p/PMA it caused a two-
fold increase in TGF-#3l mRNA levels over the subsequent 12
h (Fig. 5, a and b). In contrast, when dexamethasone was added
to cultures 20 h after PHA-sp/PMA, it was ineffective in elevat-
ing TGF-3l mRNA levels in T cells (Fig. 5 c). Similar results
were obtained in experiments with T cells from seven addi-
tional individuals.
Effect ofcycloheximide on dexamethasone-stimulated ex-
pression of TGF-f3 gene by activated T cells. We next investi-
gated whether dexamethasone-induced stimulation ofTGF-#lI
mRNA expression by PHA-p/PMA activated T cells required
de novo protein synthesis. In experiments not shown, we found
that 30 ,g/ml cycloheximide caused > 97% inhibition of 14C-
leucine incorporation into newly synthesized protein in PHA-
p/PMA-activated T cells. Therefore, nonactivated T cells and
T cells activated with PHA-p/PMA in the presence or absence
of dexamethasone (100 ,g/ml) were cultured with cyclohexi-
mide (30 ,g/ml) for 6 h. As shown in Fig. 6, unstimulated (Fig.
6, a and b), as well as PHA-p/PMA-activated T cells cultured in
the absence (Fig. 6, c and d) or in the presence (Fig. 6, e andj)
of dexamethasone showed increased steady-state TGF-,l
mRNA levels after incubation with cycloheximide for 6 h. In
contrast, the steady-state mRNA levels for GAPD, used as a
control, did not change. Similar results were obtained in exper-
iments with T cells from five additional normal donors.
Effect ofdexamethasone on TGF-fl1 gene transcription. To
explore the level of regulation of the expression of TGF-,61
gene that is modulated by dexamethasone, in vitro nuclear
a b c
i ,r
d e f
a b c Figure 5. Effect of time
of addition of dexa-
methasone on TGF-tll2.5 k b
- * j ^'# mRNA levels in acti-
vated T cells from one
individual. Northern
hybridization analyses
were performed on total
RNA from T cells
treated with PHA-p (2
_*g/ml) and PMA (30
ng/ml) for 24 h in the
absence of dexametha-
sone (a). To identical
cultures, dexametha-
sone (200 Mg/ml) was
added at 12 h (b), or 24
h (c). Lower part ofthe
figure shows the ethid-
ium bromide-stained
formaldehyde gel with bands corresponding to 28S and 18S ribosomal
RNA. 5 ,g total RNA was loaded in each lane.
I.6kb-*4p
Figure 6. Effect of cycloheximide of TGF-#l1 mRNA levels in acti-
vated and unactivated T cells from one individual. Northern hybrid-
ization analyses were performed on total RNA from T cells that were
cultured in serum-free medium for 6 h without PHA-p/PMA (a), with
cycloheximide (b), with PHA-p/PMA (c), with PHA/PMA and cyclo-
heximide (d), with PHA-p/PMA and dexamethasone (100 Mg/ml) (e),
and PHA-p/PMA, cycloheximide, and dexamethasone (f). Lower
part of the figure shows the ethidium bromide-stained formaldehyde
gel with bands corresponding to 28S and 18S ribosomal RNA, re-
spectively. 5 Ag of total RNA was loaded in each lane. Lowest part of
the figure shows the same blot rehybridized with a [32PI-labeled
GAPD cDNA probe that hybridizes to a 1.6-kb mRNA, as described
in Methods.
Glucocorticoid Regulation of Transforming Growth Factor-flJ Expression 1577
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300 Figure 7. Dexametha-
O sone stimulation of
CL TGF-(#l gene transcrip-
<: tion. Results of three
CD
. -experiments are shown.
_
200 T cells were cultured for
6 h in the absence or
I - -presence of dexametha-
IL - - sone (200 ug/ml). TheCD
100 b bin vitro nuclear run-off
! 100 assay was performed as
D - - - - described in Methods.
a - - - - The signals were quan-
C* * * - titated by laser densi-
0 tometry. Plasmid vector
U D P P+D without insert was usedto estimate the back-
ground level, which was virtually zero. Values are expressed as percent
ofcontrol and are normalized by comparing the intensities of signals
from the experimental conditions to those obtained from control hy-
bridization with GAPD cDNA.
transcription assays were performed with nuclei isolated from
T cells that had been incubated for 6 h with PHA-p/PMA in the
presence or absence ofdexamethasone (100 ,g/ml). The results
of three experiments summarized in Fig. 7, show that the rate
of transcription of the TGF-,B1 gene is increased over twofold
by 100 ,g/ml dexamethasone, while stimulation with mitogen
did not affect the transcription rate. However, addition ofdexa-
methasone to cells incubated with mitogens, resulted in an in-
crease in the T cell TGF-,B1 gene transcription rate beyond that
seen with dexamethasone alone. These observations suggested
that dexamethasone and mitogens stimulate TGF-j31 mRNA
expression by different mechanisms.
Effect of dexamethasone on production of TGF-01 by T
cells. To ascertain whether the dexamethasone-induced in-
crease in steady-state TGF-,BI mRNA levels is accompanied by
a concomitant increase in the production ofTGF-l protein,
we determined the biological activity of TGF-#I in T cell su-
pernatants. For this purpose, T cells were cultured without
serum in the presence or absence ofPHA-p/PMA with or with-
out dexamethasone. The collected supernatants were assayed
for TGF-#31 biologic activity in the CCL64 bioassay which uses
a lung epithelial cell line (MV1 Lu) that is known to be growth
inhibited by TGF-#1 (26). As seen in Table I, whereas superna-
tants from unactivated T cells inhibited proliferation ofCCL64
cells by 27%, supernatants from activated T cells resulted in a
62% inhibition. Although the levels ofTGF-,B1 produced by T
cells showed a large variation, acidified supernatants condi-
tioned by unactivated T cells had - 8 pg/ml TGF-,Bl-like bio-
logic activity; supernatants from PHA-activated T cells had
twofold higher levels of - 16 pg/ml dexamethasone treated-
activated T cells had the highest levels of - 30 pg/ml. We
realize the shortcomings of this biological assay and are in the
process ofsetting up a more direct and sensitive ELISA assay to
confirm our present observations. The supernatants from T
cells that were activated in the presence of dexamethasone in-
duced a further inhibition to 82%. To confirm that the inhibi-
tion of CCL64 proliferation was indeed due to TGF-fl1, the
supernatants were treated with a specific anti-TGF-,3l anti-
body. The antibody significantly reduced the inhibitory effects
of supernatants from T cells activated in the presence of dexa-
Table L Effect ofSupernatants from Human T Lymphocytes on
the Proliferation ofCCL64 Cells*
Sample added [3HJ-thymidine uptake
cpm (X103)
Aim V media 53.15±2.8 (100)t
Aim V media + Dex
(50 sg/ml) 37.82±2.3 (71)
T Cell supernatants Acidified Nonacidified
Unstimulated 38.7±2.3 (73) 44.7±2.1(80)
PHA-p/PMA 20.4±1.3 (38) 22.3±4.2 (40)
PHA-p/PMA + Dex
(50 ,gg/ml) 9.6±0.9 (18)f 17.4±1.8 (31)
PHA-p/PMA + Dex
+ anti-TGFOB-l 44.5±0.5 (80)11 ND
TGF#-I standard 7.9±1.3 (6.8) ND
TGFO-1 standard
+ anti-TGF#3-l 32.5±1.7 (58) ND
* Supernatants from T cells cultured under various experimental
conditions were added to preconfluent cultures of CCL64 cells and
the [3H]-thymidine incorporation into macromolecular DNA was
determined as described in Methods. Each supernatant was tested in
triplicate and the values shown are the averages of [3H]-thymidine
incorporation expressed as cpm X 10-3_2 SD. Data presented in this
table represent results obtained with 1 :10,000 dilution of the T cell
supernatants as well as conditioned media. TGF-#1 standard was used
at a final concentration of 0.04 ng/ml. In certain experiments the
anti-TGF#3 antibody AB-IO-NA (R and D Systems) was added as de-
scribed in Methods. ND, not tested. * Numbers in parentheses indi-
cate percent proliferation of CCL64 cells. I P < 0.01 compared to
cpm of samples cultured without dexamethasone. 1I P < 0.01 com-
pared to cpm of respective samples that were cultured without anti-
body.
methasone indicating that these samples contained TGF-f3l
activity which was blocked by the addition of an anti-TGF-,Bl
antibody (Table I). Although the majority of TGF-(#1 activity
was obtained after acidification of supernatants, unacidified
supernatants also contained TGF-,31 activity, although to a
lesser extent compared to acid-activated samples, i.e., 69% vs.
82% after acidification. Whether the majority of dexametha-
sone-induced TGF-#31 is in latent form will be tested by experi-
ments in which we shall compare antibody neutralization of
acidified versus nonacidified supernatants. The presence of
TGF-, I in supernatants ofactivated peripheral blood lympho-
cytes and T cells was further demonstrated by immunoblot
analysis. A representative example from four experiments is
seen in Fig. 8 and shows that both peripheral blood lympho-
cytes and T cells produce immuno-detectable TGF-j31 that ap-
pears to be highest in concentration in dexamethasone-treated
T cell supernatants.
Discussion
In this study we examined the regulation of TGF-#lI gene ex-
pression by dexamethasone in normal human T cells activated
by PHA-p and PMA. The results show that dexamethasone
significantly enhances the expression of the TGF-,B1 gene and
the production of the corresponding protein by activated T
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Figure 8. Dexamethasone-mediated stimulation of TGF-f,1 produc-
tion by activated lymphocytes. Immunoblot analysis was performed
with supernatants from pHA-p/PMA-treated PBL and T cells ofone
individual, that were cultured with or without dexamethasone (100
,ug/ml), and were visualized with a rabbit anti-TGFB-l antibody as
described in Methods.
cells in a dose and time dependent fashion. Although the biolog-
ical significance of this finding is unknown, the increased syn-
thesis of an immunosuppressor cytokine could be one mecha-
nism by which GC mediate immunosuppression. Since TGF-
,B1 is a potent inhibitor of T cell proliferation, its increased
synthesis by activated T cells could be a biologic mechanism by
which T cells limit the extent of their proliferative response to
antigenic stimulation.
Stimulation and subsequent activation ofT cells by specific
antigens or by mitogens requires two signals: (a) the occupation
ofthe T cell antigen receptor, an effect which can be mimicked
by PHA-p; and (b) an effect of accessory cells, mimicked by
agents that activate protein kinase C, such as phorbol esters (6,
31, 32). In response, multiple T cell genes are sequentially acti-
vated, over a period ofseveral days (33), resulting in blastogen-
esis within 12 h, cell division by 24-48 h, with subsequent
differentiation into immunocompetent T cells. Our time
course experiments demonstrate that dexamethasone exercises
its effect on TGF-f,1 gene expression only during the first 12 h
after activation, a time period corresponding to the blast trans-
formation stage ofT cell activation. Dexamethasone has other
effects as well. For example, dexamethasone is known to in-
hibit gene expression of IL-2 and y-IFN, both of which are
expressed during the initial 2 h ofT cell activation with PHA-p
and PMA (4). We have reported that dexamethasone signifi-
cantly decreases cell surface expression ofthe high affinity IL-2
receptor (IL-2R) in PHA-p/PMA activated T cells in a similar
time frame (34), suggesting that during the initial 12 h ofT cell
induction, expression of several genes important in the regula-
tion ofT cell activation can be modulated by dexamethasone.
More recently it was found that TGF-,B1 can inhibit the progres-
sion of activated T cells from the G1 to the S phase of the cell
cycle and can inhibit IL-2R generation in murine T cell lines
(35). Taken together, these observations raise the possibility
that inhibition ofT cell proliferation and IL-2R generation in
vivo may be mediated or potentiated by TGF-,lB, and thus,
that TGF-#1 may play a pivotal role in some human diseases.
However, although TGF-#1 can regulate expression ofthe IL-2
receptor in T cell lines, whether it alters IL-2 gene expression in
human T cells is not clear (36). Thus, it is unlikely that TGF-1 I
alone is responsible for the inhibitory effects of GC on T cell
functions. Physiologic variations of plasma GC levels make it
difficult to assess the role of endogenous GC in modulating
TGF-#l1 expression. It would be interesting to compare TGF-
,B1 expression by T cells during periods ofnormal and elevated
plasma GC levels, such as during stress when IL-2R expression
and T cell activation are both decreased (37, 38).
The superinduction of TGF-fl1 mRNA caused by cyclo-
heximide suggests that de novo protein synthesis is required for
TGF-fll mRNA degradation in T cells (39). Whether dexa-
methasone inhibits a short half-lived ribonuclease(s) that de-
grades TGF-# I mRNA or it acts by a posttranslational mecha-
nism that is coupled to TGFfB-mRNA degradation is not
known. Since cycloheximide would inhibit new TGF-#l syn-
thesis by PHA-p/PMA-stimulated T cells, upregulation of its
mRNA by the cytokine itselfcannot account for the cyclohexi-
mide-induced increase in steady state mRNA levels for
TGF-(1l.
Promoters that contain positive and negative regulatory re-
gions, upstream and downstream of the transcriptional start
site of the TGF-f31 gene, have been identified in humans (40,
41). The positive regulatory regions of the upstream promoter
for TGF-fll contain binding sites for known transcription fac-
tors including NF-1, SPI, and APl that could mediate tran-
scriptional regulation by GC. Corticosteroid-receptor com-
plexes are known to regulate the expression ofa variety ofgenes
by stimulating the activity oftranscription factor binding sites,
including NF- 1, SP1, as well as AP-l either by direct binding or
indirectly, by cooperation with other binding factors (42). The
in vitro nuclear transcription assays described here indicate
that the increase in TGF-# I gene expression induced by dexa-
methasone occurs mostly at a transcriptional level whereas
stimulation by mitogens appears to occur at least in part post-
transcriptionally. This is not surprising since it is known that
TGF-#l steady-state mRNA levels can be modulated through
multiple pathways. Regulation ofthe TGF-#3I gene is posttran-
scriptional in certain glioblastoma and neuroblastoma cell
lines (22), and transcriptional in fibroblast cell lines in which
TGF-#31 induces its own gene activation (19), and is transla-
tional in an osteoblast-like cell line in response to fibroblast
growth factor (43).
Both TGF-# I and GC affect the functions ofa wide variety
of cells. Whether the dexamethasone effect on TGF-#31 expres-
sion might be found in B cells, steroid responsive-leukemia
cells, or in other hemopoietic cells, and, if so, whether this is a
biologically relevant effect, remains to be answered by future
studies.
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